Is There a Role for Triple Therapy After ACS?. [Review]
Citation: Current Cardiology Reports. 24(3):191-200, 2022 Mar.PMID: 35112242Institution: MedStar Washington Hospital CenterDepartment: Advanced Cardiac Catheterization Research FellowshipForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Acute Coronary Syndrome | *Atrial Fibrillation | *Percutaneous Coronary Intervention | Acute Coronary Syndrome/co [Complications] | Acute Coronary Syndrome/dt [Drug Therapy] | Administration, Oral | Anticoagulants/ae [Adverse Effects] | Atrial Fibrillation/co [Complications] | Atrial Fibrillation/dt [Drug Therapy] | Drug Therapy, Combination | Fibrinolytic Agents/ae [Adverse Effects] | Humans | Platelet Aggregation Inhibitors/ae [Adverse Effects]Year: 2022Abstract: PURPOSE OF REVIEW: The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients.RECENT FINDINGS: The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events. Copyright (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Originally published: Current Cardiology Reports. 2022 Feb 02Fiscal year: FY2022Digital Object Identifier: Date added to catalog: 2022-02-22| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | 35112242 | Available | 35112242 |
PURPOSE OF REVIEW: The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients.
RECENT FINDINGS: The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events. Copyright (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
English